REAL-WORLD STUDY OF METASTATIC MERKEL CELL CARCINOMA PATIENTS RECEIVING CHECKPOINT INHIBITORS (CPIS) VS. CHEMOTHERAPY TREATMENTS

被引：0
|
作者：
Zheng, Y. [1 ]
Kim, R. [2 ]
Yu, T. [1 ]
Dreyfus, J. [3 ]
Gayle, J. A. [3 ]
Wassel, C. L. [3 ]
Phatak, H. [1 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Pfizer Inc, New York, NY USA
[3] Premier Inc, Charlotte, NC USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.435
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN317
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [41] Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non-small cell lung cancer.
    Hong, Lingzhi
    Rinsurongkawong, Waree
    Saad, Maliazurina B.
    Chen, Pingjun
    Aminu, Muhammad
    Spelman, Amy R.
    Negrao, Marcelo Vailati
    Cascone, Tina
    Lin, Steven H.
    Lee, Percy
    Sepesi, Boris
    Lewis, Jeff
    Gibbons, Don Lynn
    Vaporciyan, Ara A.
    Lee, J. Jack
    Le, Xiuning
    Wu, Jia
    Heymach, John
    Zhang, Jianjun
    Vokes, Natalie I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Merkel polyomavirus antibody testing for detecting recurrent Merkel cell carcinoma: A prospective, real-world outcomes study
    Gunnell, L.
    Akaike, T.
    Lachance, K.
    Hippe, D. S.
    Cahill, K.
    Doolittle-Amieva, C.
    Zawacki, L.
    Park, S.
    Nghiem, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S96 - S96
  • [43] Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database
    Fan, Qianqian
    Chen, Huan
    Hu, Yang
    Zhao, Bin
    CUTANEOUS AND OCULAR TOXICOLOGY, 2023, 42 (02) : 68 - 73
  • [44] Real-world evidence in metastatic renal cell carcinoma
    Graham, Jeffrey
    Heng, Daniel Y. C.
    TUMORI JOURNAL, 2018, 104 (02): : 76 - 82
  • [45] Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
    Levy, Sonja
    Aarts, Maureen J. B.
    Eskens, Ferry A. L. M.
    Keymeulen, Kristien B. M., I
    Been, Lukas B.
    Grunhagen, Dirk
    van Akkooi, Alexander
    Jalving, Mathilde
    Tesselaar, Margot E. T.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [46] Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyosuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Nonomura, Norio
    Uemura, Motohide
    ANTICANCER RESEARCH, 2021, 41 (11) : 5811 - 5816
  • [47] Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
    Matteo Santoni
    Francesco Massari
    Enrique Grande
    Giuseppe Procopio
    Marc R. Matrana
    Mimma Rizzo
    Ugo De Giorgi
    Umberto Basso
    Michele Milella
    Roberto Iacovelli
    Gaetano Aurilio
    Lorena Incorvaia
    Sebastiano Buti
    Orazio Caffo
    Giuseppe Fornarini
    Francesco Carrozza
    Veronica Mollica
    Alessandro Rizzo
    Fady Farag
    Javier Molina-Cerrillo
    Nicola Battelli
    Targeted Oncology, 2021, 16 : 625 - 632
  • [48] Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
    Santoni, Matteo
    Massari, Francesco
    Grande, Enrique
    Procopio, Giuseppe
    Matrana, Marc R.
    Rizzo, Mimma
    De Giorgi, Ugo
    Basso, Umberto
    Milella, Michele
    Iacovelli, Roberto
    Aurilio, Gaetano
    Incorvaia, Lorena
    Buti, Sebastiano
    Caffo, Orazio
    Fornarini, Giuseppe
    Carrozza, Francesco
    Mollica, Veronica
    Rizzo, Alessandro
    Farag, Fady
    Molina-Cerrillo, Javier
    Battelli, Nicola
    TARGETED ONCOLOGY, 2021, 16 (05) : 625 - 632
  • [49] Comprehensive immune profiling of patients (pts) with metastatic urothelial cancer (mUC) or renal cell cancer (mRCC) receiving immune checkpoint inhibitors (CPIs)
    Lavoie, Jean-Michel
    Nissen, Michael
    Baichoo, Priya
    Nappi, Lucia
    Khalaf, Daniel Joseph
    Kollmannsberger, Christian K.
    Chi, Kim N.
    Weng, Andrew
    Eigl, Bernhard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [50] Efficacy and safety of immune checkpoint inhibitors in older HCC patients: A real-world study
    Cheng, J.
    Chen, B.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S338 - S338
12345